氮芥
医学
耐受性
不利影响
鼻喷雾剂
组胺H1受体
麻醉
随机对照试验
内科学
鼻腔给药
敌手
药理学
受体
作者
I. Antépara,I Jáuregui,A. Basomba,A. Cadahia,Feo F,Jorge Garcia,M A Gonzalo,Iben Engelund Luna,Elena Múñez,Marta Vázquez
出处
期刊:PubMed
日期:1998-05-20
卷期号:26 (1): 9-16
被引量:2
摘要
The efficacy and safety of the nasally administered histamine H1 receptor blocking drug Azelastine was investigated in an open, multicenter, randomized comparative trial with Ebastine in seasonal allergic rhinitis. 110 patients in two parallel groups were treated for 14 days and efficacy was assessed by the physician using a rating scale measuring 10 nasal and ocular symptoms of seasonal rhinitis (0 = absent, 1 = mild, 2 = moderate, 3 = severe). Tolerability was measured on the basis of reported adverse events. Both treatment groups had dramatic reductions in the physician's total symptom score following treatment (p < 0.0005). There was no significant difference between the two groups. Changes in individual rhinitis symptoms showed no differences between the two groups. During treatment, 19 patients had at least one adverse event, 13 in Azelastine group and 6 in Ebastine group; all were mild. The most frequent adverse events reported were somnolence (4 cases in Ebastine group) and a bitter taste (4 patients in the Azelastine group). In conclusion, the results of the study on 110 patients suggest that both Azelastine and Ebastine are effective treatments of the symptoms of seasonal allergic rhinitis. Both drugs were well tolerated.
科研通智能强力驱动
Strongly Powered by AbleSci AI